Regulatory

Therapeutics have become increasingly complex and development timelines are often sharply compressed to meet urgent medical needs. BioTechLogic is thoroughly versed in the current requirements of the world’s leading regulatory bodies, allowing us to serve as a trusted guide on your journey to market.

FDA

  • Orphan drug designation
  • Rare pediatric disease
  • Fast track designation
  • Breakthrough therapy designation
  • RMAT designation

EMA

  • Accelerated assessment
  • Conditional marketing authorization
  • Authorization under exceptional circumstances
  • PRIME designation


MHRA

  • Innovative licensing and access pathway


Visit DHC's site for additional Regulatory services:

Regulatory filing planning & readiness

With comprehensive global regulatory and CMC strategies knowledge, we offer technical evaluations of regulatory submission source reports and commercialization and submission readiness gap assessments.

Filing preparation, review & publishing

Preparation and/or review of regulatory documentation, including briefing packages, IND, BLA, NDA, IMPD, MAA, supplements/variations, or rest of world (ROW) filings. After an expert review of regulatory submissions before filing, we offer publishing support.

Regulatory body liaison

BioTechLogic offers full support, whether in response to a request for information or in managing an FDA warning letter or other communication.

Accelerated filing support

In addition to increased therapeutic complexity, leading regulatory bodies now offer many more options for accelerating drug products meeting critical unmet medical needs. BioTechLogic provides the expertise to navigate the multitude of approval options and manage drastically accelerated programs.

Combination products regulatory support

BioTechLogic assists companies by supporting the registration of drug-device combination products. We have experience with each constituent part and the GMP regulations that together form the basis for their development and manufacture: Drug (21 CFR 210/211), Biologics (21 CFR 600), Device (21 CFR 820) and Combination Products (21 CFR Part 4). BioTechLogic’s team can guide you through the matrix of requirements.

Regulatory Support for combination products includes the following:

  • Generate and review the CMC sections of regulatory submissions that support combination products [e.g., 3.2.P.2.4, 3.2.P.3.3, 3.2.P.7, and 3.2.R.4: Medical Devices (Device Design Controls), etc.]

EU combination product support

  • Prepare General Safety and Performance Requirements (GSPR) reports
  • Obtain the opinion of a notified body
Regulatory compliance, SOP generation & submission support

We support end-to-end traceability of analytical data from collection and analysis to data management for your quality system, regulatory filings, CMC submission summaries, and beyond. Additionally, we assist with SOP generation and management to ensure excellence in analytical execution.

BTL Experts in

Regulatory

In need of a business consult?

We're here to help.
Request Consultation
Text Link
Regulatory
Text Link
Nonclinical
Text Link
Quality & Compliance
Text Link
Business Analytics
Text Link
Clinical